```
1
         UNITED STATES PATENT AND TRADEMARK OFFICE
 2
          BEFORE THE PATENT TRIAL AND APPEAL BOARD
 3
 4
                 MYLAN PHARMACEUTICALS INC.
                      and PFIZER INC.,
 5
                        Petitioners,
 6
                             v.
 7
              SANOFI-AVENTIS DEUTSCHLAND GMBH,
                       Patent Owner.
 8
9
    VOLUME I
                                               Pages 1-109
10
                      Case IPR2018-01670
                      Case IPR2018-01678
11
                      Case IPR2018-01675
                      Case IPR2018-01676
12
                      Case IPR2018-01679
                      Case IPR2018-01680
13
                      Case IPR2018-01682
                      Case IPR2018-01684
14
                      Case IPR2019-00122
                     Patent No. 8,603,044
15
                     Patent No. 8,679,069
                     Patent No. 8,992,486
16
                     Patent No. 9,526,844
                     Patent No. 9,604,008
17
18
      DEPOSITION OF KARL ROBERT LEINSING, MSME, P.E.
19
            Thursday, October 10, 2019, 8:57 a.m.
20
            Sheraton Portsmouth Harborside Hotel
21
                       250 Market Street
22
              Portsmouth, New Hampshire 03801
23
    -- Reporter: Kimberly A. Smith, CSR CRR, CRC, RDR --
24
               Realtime Systems Administrator
25
                   Alderson Court Reporting
```

1-800-FOR-DEPO

www.AldersonReporting.com



```
1
    APPEARANCES:
 2
 3
        Wilson Sonsini Goodrich & Rosati, P.C.
        By:
             Richard Torczon, Esq.
 5
        and Tasha Thomas, Esq.
 6
        1700 K Street, N.W., Fifth Floor
 7
        Washington, D.C. 20006-3814
 8
        (202) 973-8800
9
        rtorczon@wsgr.com
10
        tthomas@wsgr.com
11
                     for the Petitioner Mylan
12
                     Pharmaceuticals Inc.;
13
14
        Winston & Strawn LLP
15
              Jovial Wong, Esq.
        By:
16
        1700 K Street, N.W.
17
        Washington, D.C.
                            20006
18
        (202) 282-5000
19
        jwong@winston.com
20
                     for the Petitioner Pfizer, Inc.
21
22
23
24
25
```

1-800-FOR-DEPO

www.AldersonReporting.com



```
1
    APPEARANCES: (continued)
 2
 3
        Weil, Gotshal & Manges LLP
        By: Sutton Ansley, Esq.
 5
        2001 M Street, N.W., Suite 600
 6
        Washington, D.C.
                           20036
 7
        (202) 682-7000
 8
        sutton.ansley@weil.com
9
             and
10
        Weil, Gotshal & Manges LLP
11
        By: Anish Desai, Esq.
12
        767 Fifth Avenue
13
        New York, NY 10153-0119
14
        (212) 310-8000
15
        anish.desai@weil.com
16
             and
17
        Fish & Richardson, P.C.
18
        By: Matt Colvin, Esq.
19
        601 Lexington Avenue, 52nd Floor
20
        New York, NY 10022
21
        (212) 765-5070
22
        colvin@fr.com
23
             and
24
25
```

1-800-FOR-DEPO

www.AldersonReporting.com

```
1
    APPEARANCES: (continued)
 2
 3
         Fish & Richardson, P.C.
 4
         By:
              John S. Goetz, Esq.
 5
         1717 Main Street, Suite 5000
 6
         Dallas, TX 75201
 7
         (214) 747-5070
 8
         goetz@fr.com
 9
                      for the Patent Owner.
10
11
    Also Present: Matthew Greinert, Esq., Mylan
12
13
14
15
16
17
18
19
20
21
22
23
24
25
```

1-800-FOR-DEPO

www.AldersonReporting.com



1	INDEX		
2			
3	WITNESS: Karl	Robert Leinsing, MSME, P.E.	
4			
5	EXAMINATION		Page
6	By Mr. Ansley 7		7
7	By Mr. Colvin		45
8	AFTERNOON SESSION		
9	By Mr. Colv	in	92
10			
11	EXHIBITS FOR ID	ENTIFICATION:	
12	Mylan	Description	Page
13	Exhibit 1001	U.S. Patent 8,679,069	22
14	Exhibit 1002	U.S. Patent 8,603,044	22
15	Exhibit 1003	U.S. Patent 8,992,486	32
16	Exhibit 1004	U.S. Patent 9,526,844	22
17	Exhibit 1005	U.S. Patent 9,604,008	22
18	Exhibit 1014	U.S. Patent 6,235,004	99
19	Exhibit 1016	U.S. Patent 6,932,794	37
20	Exhibit 1095	9/18/19 Leinsing reply	8
21		declaration	
22	Exhibit 1096	9/18/19 Leinsing declaration	45
23		in support of petitioners'	
24		oppositions to Sanofi's	
25		motion to amend	

1-800-FOR-DEPO

www. Alders on Reporting. com



# DOCKET A L A R M

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

